NYSE American - Delayed Quote USD
Zomedica Corp. (ZOM)
At close: October 25 at 4:00 PM EDT
After hours: October 25 at 7:59 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
26,077.0000
25,186.0000
18,930.0000
4,133.0000
--
--
Cost of Revenue
8,163.0000
7,868.0000
5,462.0000
1,079.0000
--
--
Gross Profit
17,914.0000
17,318.0000
13,468.0000
3,054.0000
--
--
Operating Expense
54,681.0000
48,910.0000
35,391.0000
24,428.0000
16,764.9780
--
Operating Income
-36,767.0000
-31,592.0000
-21,923.0000
-21,374.0000
-16,764.9780
--
Net Non Operating Interest Income Expense
4,654.0000
5,283.0000
2,700.0000
351.0000
32.1270
--
Other Income Expense
-25,644.0000
-9,551.0000
-158.0000
306.0000
-178.9330
--
Pretax Income
-57,757.0000
-35,860.0000
-19,381.0000
-20,717.0000
-16,911.7840
--
Tax Provision
-1,771.0000
-1,331.0000
-2,366.0000
-2,333.0000
--
--
Net Income Common Stockholders
-55,986.0000
-34,529.0000
-17,015.0000
-50,423.0000
-16,911.7840
--
Diluted NI Available to Com Stockholders
-55,986.0000
-34,529.0000
-17,015.0000
-50,423.0000
-16,911.7840
--
Basic EPS
-0.06
-0.04
-0.02
-0.05
-0.05
--
Diluted EPS
-0.06
-0.04
-0.02
-0.05
-0.05
--
Basic Average Shares
979,949.6680
979,949.6680
979,949.6680
956,533.7610
364,444.6640
--
Diluted Average Shares
979,949.6680
979,949.6680
979,949.6680
956,533.7610
364,444.6640
--
Total Operating Income as Reported
-52,791.0000
-31,592.0000
-21,923.0000
-21,374.0000
-16,764.9780
--
Rent Expense Supplemental
--
--
--
--
299.9470
32.4730
Total Expenses
62,844.0000
56,778.0000
40,853.0000
25,507.0000
16,764.9780
--
Net Income from Continuing & Discontinued Operation
-55,986.0000
-34,529.0000
-17,015.0000
-18,384.0000
-16,911.7840
--
Normalized Income
-28,979.3004
-23,329.7028
-16,882.4338
-18,609.3963
-16,724.2500
--
Interest Income
4,717.0000
5,458.0000
2,701.0000
357.0000
32.8590
--
Interest Expense
63.0000
175.0000
1.0000
6.0000
0.7320
--
Net Interest Income
4,654.0000
5,283.0000
2,700.0000
351.0000
32.1270
--
EBIT
-57,694.0000
-35,685.0000
-19,380.0000
-20,711.0000
-16,911.0520
--
EBITDA
-50,320.0000
-29,387.0000
-15,338.0000
-19,572.0000
-16,381.0320
--
Reconciled Cost of Revenue
8,163.0000
7,868.0000
5,462.0000
1,079.0000
--
--
Reconciled Depreciation
7,374.0000
6,298.0000
4,042.0000
1,139.0000
530.0200
--
Net Income from Continuing Operation Net Minority Interest
-55,986.0000
-34,529.0000
-17,015.0000
-18,384.0000
-16,911.7840
--
Total Unusual Items Excluding Goodwill
-27,861.0000
-11,631.0000
-151.0000
254.0000
-187.5340
--
Total Unusual Items
-27,861.0000
-11,631.0000
-151.0000
254.0000
-187.5340
--
Normalized EBITDA
-22,459.0000
-17,756.0000
-15,187.0000
-19,826.0000
-16,193.4980
--
Tax Rate for Calcs
0.0000
0.0000
0.0001
0.0001
--
--
Tax Effect of Unusual Items
-854.3004
-431.7028
-18.4338
28.6037
--
--
12/31/2019 - 11/21/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
SENS Senseonics Holdings, Inc.
0.3380
-2.99%
AIMD Ainos, Inc.
0.5600
+3.74%
BBLG Bone Biologics Corporation
1.7300
+0.58%
VTAK Catheter Precision, Inc.
0.6201
-29.17%
TNON Tenon Medical, Inc.
3.6200
-1.09%
NXL Nexalin Technology, Inc.
2.2900
+6.51%
NUWE Nuwellis, Inc.
1.8600
+13.41%
INBS Intelligent Bio Solutions Inc.
1.5600
+8.33%
BFLY Butterfly Network, Inc.
1.8200
+3.41%
VREX Varex Imaging Corporation
12.91
+0.70%